BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Norway. The company is dedicated to developing innovative drugs for aggressive diseases. BerGenBio is focused on creating a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. They are globally recognized for their understanding of the central role of AXL kinase in promoting cancer spread, immune evasion, and drug resistance, which accounts for approximately 90 percent of cancer deaths. The company's approach to inhibiting AXL kinase activity provides a novel strategy to address a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering new therapeutic options for cancer patients. Post-IPO Debt investment of kr250.00M in November 2023 demonstrates the confidence in BerGenBio's approach and potential in the biotechnology and pharmaceutical industries.